[company_age]5.0[/company_age][employees]2-10 employees[/employees][funding]Series A[/funding][description]DeepLife is a cutting-edge biotechnology company established in 2019 by Jonathan Baptista and Jean-Baptiste Morlot. Backed by international investors, DeepLife is pioneering the development of the first SaaS platform for Digital Twin of cells. Their mission is to revolutionize the field of drug discovery by leveraging the power of AI and multi-omics data to model and engineer cell behavior. DeepLife's unique approach combines state-of-the-art deep learning algorithms with extensive public and private cell atlases, enabling the identification of molecular triggers that drive cell behavior. This innovative platform empowers researchers to supplement in vitro testing with in silico simulations, significantly accelerating the drug discovery process. DeepLife's commitment to collaboration is evident in their partnerships with biotech and pharmaceutical companies, as well as their active engagement with the academic community through open-access features and publications. DeepLife's dedication to scientific advancement and its groundbreaking technology position it as a leader in the field of digital twins and personalized medicine.[/description][ps]DeepLife offers a SaaS platform for Digital Twin of cells, which includes:\n\n* DeepLife Datastore: Access to harmonized, ML-ready multi-omics datasets from over 30 qualified data repositories.\n* DeepLife Analysis: Large-scale multi-omics data analysis workflow with state-of-the-art tools and 24/7 support.\n* DeepLife Virtual Cell: Interpretable AI for System Biology, enabling target identification, pathway analysis, and disease-specific cell model training.[/ps]